Document is current
Any future updates will be listed below
-
Authors
Pezzati, Irène
Hammoum, Thania
Teko-Agbo, Clémentine Ayélé
Konate, Karidia
Beranger, Mathieu
Vivès, Eric
Chibon, Frédéric
Faure, Sandrine
de Santa Barbara, Pascal
Serrano, César
Deshayes, Sébastien
Boisguérin, Prisca
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-21-CE17-0017)
Agence Nationale de la Recherche (ANR-23-CE14-0071)
Agence Nationale de la Recherche (ANR-21-CE18-0022-01)
- License Information
-
More Information
Article History
Received: 15 September 2025
Accepted: 28 March 2026
First Online: 24 April 2026
Declarations
:
: Not applicable.
: Not applicable.
: C.S. has received research funding (institution) from IDRX, Blueprint, Karyopharm, Pfizer, Deciphera, and Bayer; consulting fees (advisory role) from IDRX, CogentBio, Immunicum AB, Deciphera, and Blueprint; payment for lectures from Deciphera, PharmaMar, Pfizer, Bayer, and Blueprint; and travel grants from PharmaMar, Gilead, Pfizer, and Bayer. The remaining authors declare no competing interests.
